Age-stratified effect of the relative infectiousness of the asymptomatic population, with respect to the symptomatic population, on the average peak hospitalization and total number of deaths for a vaccine that does not prevent transmission but can reduce symptoms in case of inadequate primary response (I1-S0), assuming 50% efficacy, 50% coverage, 6-month durability, and early vaccination (on or before Month 2).